<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04137510</url>
  </required_header>
  <id_info>
    <org_study_id>C1703</org_study_id>
    <nct_id>NCT04137510</nct_id>
  </id_info>
  <brief_title>Bioflow-DAPT Study</brief_title>
  <official_title>A Prospective, Randomized, Multi-center Study to Assess the Safety of the Orsiro Mission Stent Compared to the Resolute Onyx Stent in Subjects at High Risk for Bleeding in Combination With 1-month Dual Antiplatelet Therapy (DAPT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BIOFLOW-DAPT is a prospective, multi-center, international, two-arm randomized controlled&#xD;
      clinical study.&#xD;
&#xD;
      A total of 1'948 subjects will be randomized 1:1 to receive either Orsiro or Resolute Onyx.&#xD;
      After index procedure, all patients will receive DAPT (ASA + P2Y12 inhibitor) for 30 days,&#xD;
      followed by monotherapy with either P2Y12 inhibitor or ASA only until the end of the study.&#xD;
&#xD;
      Clinical follow-up visits will be scheduled at 1, 6 and 12 months post-procedure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, multi-center, international, two-arm randomized controlled clinical study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of cardiac death, myocardial infarction (MI) and definite or probable stent thrombosis at 12 months</measure>
    <time_frame>12 months post-procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of definite/probable stent thrombosis according to the ARC definition</measure>
    <time_frame>until 12 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of MACCE</measure>
    <time_frame>until 12 months post-procedure</time_frame>
    <description>composite of all-cause death, MI, and stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of MACE</measure>
    <time_frame>until 12 months post-procedure</time_frame>
    <description>composite of cardiac death, MI, and Target Vessel Revascularization (TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of cardiac death or MI</measure>
    <time_frame>until 12 months post-procedure</time_frame>
    <description>all, target vessel related MI, Q-wave and non Q-wave, ST-related and non ST-related</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of all-cause death, cardiac, non-cardiac</measure>
    <time_frame>until 12 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of stroke, ischemic and hemorrhagic</measure>
    <time_frame>until 12 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of clinically-indicated TVR</measure>
    <time_frame>until 12 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of clinically-indicated Target Lesion Revascularization (TLR)</measure>
    <time_frame>until 12 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Target Vessel Failure (TVF)</measure>
    <time_frame>until 12 months post-procedure</time_frame>
    <description>Composite of clinically-driven TVR, cardiac death or target-vessel related MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of target lesion failure (TLF)</measure>
    <time_frame>until 12 months post-procedure</time_frame>
    <description>Composite of clinically driven TLR, cardiac death or target vessel related MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of bleeding according to BARC definition</measure>
    <time_frame>until 12 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of bleeding according to GUSTO definition</measure>
    <time_frame>until 12 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of bleeding according to TIMI definition</measure>
    <time_frame>until 12 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Device success</measure>
    <time_frame>until 12 months post-procedure</time_frame>
    <description>Attainment of less than 30% residual stenosis of the target lesion using assigned stent only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Procedure success</measure>
    <time_frame>until 12 months post-procedure</time_frame>
    <description>Attainment of less than 30% residual stenosis of the target lesion using assigned stent only without occurrence of in-hospital major adverse cardiac events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1948</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Orsiro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Resolute Onyx</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous coronary intervention</intervention_name>
    <description>It's a non-surgical procedure that uses a catheter to place a stent into a coronary blood vessel in order to open up the vessel.</description>
    <arm_group_label>Orsiro</arm_group_label>
    <arm_group_label>Resolute Onyx</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is acceptable candidate for treatment with a DES&#xD;
&#xD;
          2. Subject is considered at high bleeding risk (HBR), defined as meeting one or more of&#xD;
             the following criteria at the time of enrollment:&#xD;
&#xD;
               1. ≥ 75 years of age&#xD;
&#xD;
               2. Moderate (estimated GFR 30-59 ml/min) or severe (estimated GFR &lt; 30 ml/min)&#xD;
                  chronic kidney disease or failure (dialysis dependent)&#xD;
&#xD;
               3. Advanced liver disease, defined as having cirrhosis with or without portal&#xD;
                  hypertension and with or without gastroesophageal varices.&#xD;
&#xD;
               4. Cancer (excluding non-melanoma skin cancer) diagnosed or treated within the&#xD;
                  previous 12 months or actively treated&#xD;
&#xD;
               5. Anemia with hemoglobin &lt; 11.0 g/dL or requiring transfusion within 4 weeks prior&#xD;
                  to randomization&#xD;
&#xD;
               6. Baseline thrombocytopenia defined as a platelet count &lt;100,000/mm3&#xD;
&#xD;
               7. History of stroke (ischemic or hemorrhagic), or brain arteriovenous malformation&#xD;
&#xD;
               8. History of hospitalization for bleeding within the previous 12 months&#xD;
&#xD;
               9. Chronic clinically significant bleeding diathesis&#xD;
&#xD;
              10. Clinical indication for chronic or lifelong oral anticoagulation (OAC) (with a&#xD;
                  vitamin K antagonist or non-vitamin K OAC)&#xD;
&#xD;
              11. Clinical indication for chronic or lifelong steroid or oral nonsteroidal&#xD;
                  anti-inflammatory drug(s) (NSAIDs), other than aspirin&#xD;
&#xD;
              12. Nondeferrable major surgery on DAPT&#xD;
&#xD;
              13. Recent major surgery or major trauma within 30 days before PCI&#xD;
&#xD;
              14. Precise DAPT score ≥ 25&#xD;
&#xD;
          3. Subject is ≥ 18 years or the minimum age required for legal adult consent in the&#xD;
             country of enrollment&#xD;
&#xD;
          4. Subject is capable (no legally authorized representative allowed) to provide written&#xD;
             informed consent as approved by the Institutional Review Board (IRB)/Ethics Committee&#xD;
             (EC) of the respective clinical site prior to any study related procedure&#xD;
&#xD;
          5. Subject is willing to comply with all protocol and follow-up requirements, including&#xD;
             agreement to discontinue DAPT at 1 month&#xD;
&#xD;
          6. Subject is eligible for dual antiplatelet therapy treatment with aspirin plus a P2Y12&#xD;
             inhibitor agent for 1-month post index procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject who previously experienced a stent or scaffold thrombosis in any coronary&#xD;
             vessel&#xD;
&#xD;
          2. Subject has a known allergy to all types of P2Y12 inhibitor (Clopidogrel, Ticagrelor,&#xD;
             Prasugrel, Ticlopidine and Cangrelor; thus preventing the use of the appropriate P2Y12&#xD;
             inhibitor), aspirin, both heparin and bivalirubin, L-605 cobalt-chromium (Co-Cr) alloy&#xD;
             or one of its major elements (cobalt, chromium, tungsten and nickel), silicon carbide,&#xD;
             PLLA, Sirolimus, or contrast media&#xD;
&#xD;
          3. Revascularization of any target vessel within 9 months prior to the index procedure or&#xD;
             previous PCI of any non-target vessel within 72 hours prior to or during the index&#xD;
             procedure&#xD;
&#xD;
          4. Subject with documented left ventricular ejection fraction (LVEF) &lt;30% as evaluated by&#xD;
             the most recent imaging exam (i.e. echocardiogram, ventriculogram, MUGA, etc.)&#xD;
&#xD;
          5. Subject judged by physician as inappropriate for discontinuation from DAPT at 1 month&#xD;
             following index procedure, due to another condition requiring chronic DAPT&#xD;
&#xD;
          6. Subject with planned surgery or procedure necessitating discontinuation of P2Y12&#xD;
             inhibitor and/or aspirin within the first month post-index procedure Note - planned&#xD;
             staged procedure at the time of index procedure is not allowed&#xD;
&#xD;
          7. Active bleeding at the time of inclusion&#xD;
&#xD;
          8. Subject with a current medical condition with a life expectancy of less than 12 months&#xD;
&#xD;
          9. Subject is currently participating or intends to participate in another&#xD;
             investigational drug or device trial within 12 months following the index procedure or&#xD;
             any other clinical trial that may interfere with the treatment or protocol of this&#xD;
             study&#xD;
&#xD;
         10. Subject is pregnant and/or breastfeeding or intends to become pregnant during the&#xD;
             duration of the study&#xD;
&#xD;
         11. In the investigator's opinion, subject will not be able to comply with the follow-up&#xD;
             requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Valgimigli, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiocentro Ticino, Via Tesserete 48, 6900 Lugano, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olga Neklyudova, PhD</last_name>
    <phone>+41 44 864 51 87</phone>
    <email>olga.neklyudova@biotronik.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Barbara Galeuchet-Schenk, PhD</last_name>
    <phone>+41 44 864 53 59</phone>
    <email>barbara.galeuchet-schenk@biotronik.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>New Lambton</city>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicholas Collins, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gabor Toth, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mathias-Christoph Brandt, Doz. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Oost Limburg Genk</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bert Ferdinande, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herlev og Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Niels Thue Olsen, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roskilde University Hospital</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Henning Kelbaek, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gilles Lemesle, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire Carémeau</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Guillaume Cayla, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Hilaire</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matthieu Godin, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Benjamin Honton, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thibault Lhermusier, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Segeberger Kliniken</name>
      <address>
        <city>Bad Segeberg</city>
        <zip>23795</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ralph Tölg, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Contilla Herz- und Gefäßzentrum</name>
      <address>
        <city>Essen</city>
        <zip>45138</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas Schmitz, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Friedrichshafen GmbH</name>
      <address>
        <city>Friedrichshafen</city>
        <zip>88048</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jochen Wöhrle, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Städtische Kliniken Neuss, Lukaskrankenhaus GmbH</name>
      <address>
        <city>Neuss</city>
        <zip>41464</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Haude, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <zip>1124</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Béla Merkely, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pécs</name>
      <address>
        <city>Pécs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Iván Horváth, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino</name>
      <address>
        <city>Milano</city>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stefano Galli, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pauls Stradins Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrejs Erglis, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1142</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jith Somaratne, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miedziowe Centrum Zdrowia</name>
      <address>
        <city>Lubin</city>
        <zip>59-301</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Adrian Wlodarczak, Dr. n. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. de Santiago de Compostela</name>
      <address>
        <city>Santiago De Compostela</city>
        <zip>15705</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ramiro Trillo Nouche, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Genève</name>
      <address>
        <city>Genève</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Juan-Fernando Iglesias, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaires Vaudoise</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephane Fournier, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CardioCentro Ticino</name>
      <address>
        <city>Lugano</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tiziano Moccetti, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de Morges</name>
      <address>
        <city>Morges</city>
        <zip>1110</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vladimir Rubimbura, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stadtspital Triemli</name>
      <address>
        <city>Zürich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Franz R. Eberli, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 22, 2019</study_first_submitted>
  <study_first_submitted_qc>October 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2019</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DAPT</keyword>
  <keyword>Dual antiplatelet therapy</keyword>
  <keyword>high bleeding risk</keyword>
  <keyword>HBR</keyword>
  <keyword>Coronary artery disease</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>PCI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

